BUZZ - Eli Lilly shares rise after raising annual revenue forecasts

October 29 - ** Eli Lilly and Company (LLY.N) shares rose 4.8% in pre-market trading to $1,350

** The pharmaceutical company raised its full-year revenue forecast from the previous $85 billion to $87 billion to $91 billion to $92 billion

** Reported third-quarter earnings per share of $7.48, above market expectations of $6.26

** The report shows that sales of diabetes drug Mounjaro in the third quarter were $10.72 billion, and sales of weight-loss drug Zepbound were $5.35 billion

** The full-year earnings per share forecast was lowered from the previous $35.50-$36.50 to $35-$36 to reflect R&D expenses from recent acquisitions

** According to data compiled by LSEG (London Stock Exchange Group), analysts had previously expected 2026 revenue to be $88.87 billion and earnings per share to be $33.88

** As of the close of the previous trading day, the stock was up about 20% for the year

(For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters assumes no responsibility for any damage or loss arising from the use of the automated translation function.)